Amgen Inc. (NASDAQ:AMGN) is Sector Gamma AS’s 9th Largest Position

Sector Gamma AS lifted its holdings in Amgen Inc. (NASDAQ:AMGN) by 187.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 46,000 shares of the medical research company’s stock after purchasing an additional 30,000 shares during the quarter. Amgen accounts for approximately 4.1% of Sector Gamma AS’s investment portfolio, making the stock its 9th largest position. Sector Gamma AS’s holdings in Amgen were worth $11,989,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. TD Private Client Wealth LLC grew its holdings in shares of Amgen by 4.6% in the fourth quarter. TD Private Client Wealth LLC now owns 22,638 shares of the medical research company’s stock valued at $5,900,000 after purchasing an additional 996 shares in the last quarter. Gutierrez Wealth Advisory LLC bought a new stake in Amgen in the fourth quarter worth $318,000. Independent Solutions Wealth Management LLC lifted its position in Amgen by 2.0% in the fourth quarter. Independent Solutions Wealth Management LLC now owns 8,913 shares of the medical research company’s stock worth $2,323,000 after buying an additional 174 shares during the last quarter. Antonelli Financial Advisors LLC bought a new stake in Amgen in the fourth quarter worth $821,000. Finally, Whittier Trust Co. of Nevada Inc. lifted its position in Amgen by 1.0% in the fourth quarter. Whittier Trust Co. of Nevada Inc. now owns 21,953 shares of the medical research company’s stock worth $5,722,000 after buying an additional 228 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $315.04 on Friday. The business’s 50 day moving average price is $296.17 and its 200 day moving average price is $299.14. The firm has a market cap of $169.24 billion, a P/E ratio of 41.73, a P/E/G ratio of 2.63 and a beta of 0.53. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, sell-side analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.02%. The ex-dividend date is Friday, May 16th. Amgen’s payout ratio is presently 126.09%.

Wall Street Analyst Weigh In

AMGN has been the subject of a number of analyst reports. Citigroup restated a “neutral” rating on shares of Amgen in a research report on Wednesday, February 5th. StockNews.com downgraded Amgen from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Piper Sandler Companies reiterated an “overweight” rating and set a $310.00 target price on shares of Amgen in a research report on Thursday, January 2nd. Royal Bank of Canada reiterated an “outperform” rating and set a $324.00 target price on shares of Amgen in a research report on Friday, January 24th. Finally, UBS Group reiterated a “hold” rating on shares of Amgen in a research report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $314.04.

Insider Buying and Selling at Amgen

In other news, EVP David M. Reese sold 25,225 shares of the company’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the transaction, the executive vice president now directly owns 36,922 shares of the company’s stock, valued at $11,240,533.68. This represents a 40.59 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of the company’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the transaction, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at approximately $2,195,228.70. The trade was a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 69,341 shares of company stock valued at $20,644,335. 0.69% of the stock is owned by company insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.